Illumina, Inc. is a life sciences company that develops, manufactures, and markets life science tools and integrated systems for genetic variation and function analysis. It operates through the Core Illumina segment that serves customers in research, clinical, and applied markets, enabling them to adopt various genomic solutions. A few institutional investors have modified their stock holdings in the company, with Toroso Investments LLC growing its position in Illumina by 3.6% during the third quarter. Meanwhile, Citigroup recently cut shares of Illumina from “neutral” to “sell,” while Piper Sandler reaffirmed an “overweight” rating and a $290.00 price objective on shares of Illumina. Illumina had a negative net margin of 96.12% and a positive return on equity of 3.79% in its latest quarterly earnings data. Finally, subscribers can sign up for MarketBeat.com’s free daily email newsletter to receive the latest news and analysts’ ratings for Illumina and related companies.
Toroso Investments LLC increases holdings in Illumina, Inc. by 3.6%
Toroso Investments LLC has increased its holdings in Illumina, Inc. (NASDAQ: ILMN) by 3.6% during the third quarter, according to the 13F filing with the SEC. The institutional investor is among several others that have made changes to their stock holdings in ILMN.
Other Institutional Investors Follow Suit
Private Trust Co. NA purchased a new stake in Illumina shares in the second quarter valued at about $25,000. In the third quarter, Zions Bancorporation N.A. boosted its holdings in the life sciences company’s stock by 97.6%, owning 164 shares valued at $31,000 after purchasing 81 additional shares. Guardian Wealth Advisors LLC also bought a new stake in ILMN shares in the third quarter valued at about $33,000. Additionally, Massmutual Trust Co. FSB ADV has increased its holdings in Illumina by 50% in the third quarter, owning 183 shares of the company’s stock valued at $35,000 after purchasing 61 additional shares. Finally, SOA Wealth Advisors LLC has increased its holdings in ILMN by 282.7% in the third quarter, owning 199 shares of the company’s stock valued at $37,000 after purchasing 147 additional shares. Currently, institutional investors own 87.97% of the company’s stock.
ILMN Stock Details
On Friday, ILMN shares opened at $224.55, with a market cap of $35.48 billion, a PE ratio of -8.02, a price-to-earnings-growth ratio of 8.32, and a beta of 1.15. The company has a 50-day simple moving average of $208.86 and a 200-day simple moving average of $208.73. It has a quick ratio of 1.08, a current ratio of 1.28, and a debt-to-equity ratio of 0.23. The company’s 52-week low is $173.45, and the 52-week high is $371.16.
Illumina’s Quarterly Earnings Report
Illumina (NASDAQ: ILMN) last released its quarterly earnings data on Tuesday, February 7th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.11). The company had revenue of $1.08 billion during the quarter, compared to the analyst’s estimate of $1.07 billion. The business’s quarterly revenue was down 9.2% compared to the same quarter last year, and its net margin was negative, at 96.12%. Despite this, the company still had a positive return on equity of 3.79%. In the same period last year, the firm earned $0.75 EPS. On average, equities analysts expect the company to post $1.41 EPS for the current year.
Insider Activity at Illumina
Insider Selling of Illumina Stock by Senior Vice Presidents
In January 2023, two senior vice presidents of Illumina, Inc. (NASDAQ: ILMN), Susan H. Tousi and Aimee L. Hoyt, sold Illumina stock in separate transactions. Tousi sold 500 shares at an average price of $204.58, while Hoyt sold 871 shares at an average price of $205.57. The total value of the shares sold by insiders in the last 90 days was $2,255,837. Tousi now owns 38,662 shares in the company, valued at $7,909,471.96, and Hoyt now owns 2,796 shares, valued at $574,773.72.
Wall Street Analysts’ Ratings
Several analysts have recently given their opinion on Illumina’s stock. Citigroup downgraded the stock from “neutral” to “sell” and lowered the price target to $180.00. Argus also downgraded the stock from “buy” to “hold” based on their valuation analysis. Scotiabank initiated coverage of Illumina with a “sector perform” rating and a price target of $216.00. SVB Leerink increased the price target to $250.00 and gave the company an “outperform” rating. Piper Sandler reaffirmed their “overweight” rating and issued a price target of $290.00. Overall, there are three “sell” ratings, six “hold” ratings, and eight “buy” ratings for Illumina’s stock, with a consensus rating of “Hold” and an average target price of $249.40.
Illumina Profile
Illumina, Inc. (NASDAQ: ILMN) is a life sciences company with a market capitalization of $35.48 billion. The stock opened at $224.55 on Friday, with a 52-week low of $173.45 and a 52-week high of $371.16. The company’s quick ratio is 1.08, and its current ratio is 1.28. The company had revenue of $1.08 billion during the last quarter, which was down 9.2% compared to the same quarter last year. The company’s net margin was negative, at 96.12%, and its positive return on equity was 3.79%. Equities analysts estimate that the company will post $1.41 earnings per share for the current year. Institutional investors currently own 87.97% of the company’s stock.
Illumina’s Core Business and Operations
Illumina, Inc. is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the large-scale analysis of genetic variation and function. The company operates through the Core Illumina segment, which caters to customers in the research, clinical, and applied markets. The segment enables the adoption of various genomic solutions for diverse applications.
Further Reading
For more information and daily updates on Illumina, you can sign up for MarketBeat.com’s FREE daily email newsletter. The newsletter provides a concise summary of the latest news and analysts’ ratings for Illumina and related companies.
Don’t miss interesting posts on Famousbio
